Neuro-Oncology Takes Center Stage Ahead of Year-End Meetings

Neuro-oncology is drawing fresh attention as the Society for Neuro-Oncology meeting approaches in Philadelphia later this month, with several companies expected to present new data.

Analysts say diagnostics and targeted therapeutics are increasingly viewed together, as clinicians look for ways to detect, characterize and monitor central nervous system cancers over time.

"Investors are paying attention to companies that connect testing, treatment and data," said one healthcare analyst. "That integrated approach is where much of the conversation is heading."

Payer coverage for cerebrospinal fluid testing is another area to watch, with insurers continuing to add in-network agreements for newer diagnostic tests.